Similarly, an engineered oncolytic HSV-1 was designed to express IL-12 and GM-CSF and such a combination effectively diminished tumor growth as well as augmented the survival rate compared to treatment with oncolytic HSV-1 expressing GM-CSF (Δ6/GM) or oncolytic HSV-1 expressing IL-12 (Δ6/IL12) alone [52]. The gene discussed is CSF2; the disease is neoplasm.